Enhanced immunostimulant activity and protective effect of asynthetic lipopetide after liposomization against Plasmodium berghei infection in mice

Journal of Drug Targeting

Volumn 9, Issue 4, 2001, Pages 231-239

  Agrawal, A K ^a   Puri, A ^a   Haq, W ^a   Gupta, C M ^a  

^a PolyMASC Pharmaceuticals plc   (United Kingdom)

Author keywords

Immunomodulation; Lipopeptide (comp.84 201); Liposome; Malaria

Indexed keywords

CARBON 14; GLUCOSAMINE; IMMUNOMODULATING AGENT; LIPOPEPTIDE; LIPOSOME; PYROGEN; SUGAR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN SPECIFICITY; ARTICLE; CHEMICAL MODIFICATION; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DRUG FORMULATION; DRUG STRUCTURE; HOST RESISTANCE; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOSTIMULATION; INFECTION RESISTANCE; LETHALITY; LIPOSOMIZATION; MACROPHAGE MIGRATION; MALE; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; PHAGOCYTOSIS; PLASMODIUM BERGHEI; PRIORITY JOURNAL; PROTECTION; PROTOZOAL INFECTION; SURVIVAL;

EID: 0034893337     PISSN: 1061186X     EISSN: None     Source Type: Journal    
DOI: 10.3109/10611860108997932     Document Type: Article

References (27)

1. Tuftsin-bearing liposomes as rifampin vehicles in treatment of tuberculosis in mice
2. Functional drug targeting to erythrocytes using antibody-bearing liposomes as drug vehicles
3. Tuftsin-bearing liposomes in treatment of macrophage-based infections
4. Antibody-bearing liposomes as chloroquine vehicles in treatment of murine malaria
5. LipoMASC™ Prototypes: Liposomal Vehicles for Enhanced Tumour Targeting and Delivery
6. Activation of macrophages by lymphokines: Enhancement of phagosome-lysosome fusion and killing of Coccidioides immitis
7. Liposomes in drug targeting
8. The Role of Spleen in Immunology of Parasitic Diseases
9. Influence of immunoadjuvants and a promiscous T-cell determinant on the immunogenecity of RESA peptide antigen of P. falciparum
10. Protection of mice against Plasmodium berghei infection by a tuftsin derivative
11. Drug targeting in Leishmania infection using tuftsin-bearing liposomes as drug vehicles
12. Liposomal muramyl tripeptide (CGP 19835A lipid) therapy for resectable melanoma in patients who were at high risk for relapse: An update
13. Effective priming of cytotoxic T lymphocyte precursors by subcutaneous administration of peptide antigens in liposomes accompanied by anti-CD40 and anti-CTLA-4 antibodies
14. Immune therapies offer glimmer of hope in HIV
15. What's new in immunomodulation?
16. Plaque formation in agar by antibody producing cells
17. Kinetics of phagocytosis and intracellular killing of Candida albicans by human granulocytes and monocytes
18. A short lipopeptide representative of a new family of immuno adjuvants devoid of sugar 2
19. Brugia malayi in Mastomys natalensis: Effect of Immunomodulators on stablishment and course of infection
20. Tuftsin-bearing liposomes as drug vehicles in treatment of experimental aspergillosis
21. Immunostimulant activity of novel Lipopeptide and its protective action against L donovani infection
22. Adjuvant activities of Quinonyl-N-acetyl muramyl dipeptide in mice and guinea pigs
23. Stimulation of non-specific resistance by thymopentin and its analogs against Leishmania donovani infection in hamsters
24. Macrophage activation by bacterial cell walls and related synthetic compounds
25. Involvement of T cells in enhanced resistance to Klebsiella pneumoniae septicemia in mice treated with liposome-encapsulated muramy tripeptide phosphatidylethanolamine or gamma interferon
26. Immunomodulation therapy in colorectal carcinoma